Effects of adenosine triphosphate on vandetanib induced skin damage in rats.


Journal

Cutaneous and ocular toxicology
ISSN: 1556-9535
Titre abrégé: Cutan Ocul Toxicol
Pays: England
ID NLM: 101266892

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 30 7 2020
medline: 24 6 2021
entrez: 30 7 2020
Statut: ppublish

Résumé

Vandetanib is a wide spectrum tyrosine kinase inhibitor used for the treatment of metastatic medullary thyroid cancer (MTC) and various other cancer types. Although it is usually well-tolerated ıt has been linked to a variety of severe dermatologic reactions. Our study aimed was to investigate adenosine 5'-triphosphate (ATP) on vandetanib-induced skin damage. A total number of 18 rats were divided into three equal groups as vandetanib group (VDB), vandetanib plus ATP group (VAT), and healthy group (HG); 25 mg/kg ATP was injected intraperitoneally (ip) to the VAT group. Normal saline was given to the HG and VDB groups as solvent via intraperitoneally. One hour later, 25 mg/kg vandetanib was applied orally via an orogastric catheter in the VAT and VDB groups. This procedure was repeated once daily for 4 weeks. After that period, all animals were sacrificed and their skin tissues removed. Malondialdehyde (MDA), total glutathione (tGSH), total oxidant status (TOS), total antioxidant status (TAS) levels in rats' skin tissues were evaluated with histopathological analyses. MDA and TOS levels measured higher in the VDB group compared to the VAT and HG groups ( We demonstrated that adenosine triphosphate can prevent vandetanib-induced skin toxicity in rats for the first time. The promising results denote that further studies testing this agent in other animal models and in humans are warranted.

Identifiants

pubmed: 32722951
doi: 10.1080/15569527.2020.1802742
doi:

Substances chimiques

Antineoplastic Agents 0
Piperidines 0
Protein Kinase Inhibitors 0
Quinazolines 0
Malondialdehyde 4Y8F71G49Q
Adenosine Triphosphate 8L70Q75FXE
Glutathione GAN16C9B8O
vandetanib YO460OQ37K

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-327

Auteurs

Baran Akagunduz (B)

Department of Medical Oncology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.

Fatih Ozcicek (F)

Department of Internal Medicine, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.

Ali Veysel Kara (AV)

Department of Internal Medicine, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.

Deniz Can Guven (DC)

Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Gulce Naz Yazici (GN)

Department of Histology and Emryology, Faculty of Science and Art, Erzincan Binali Yildirim University, Erzincan, Turkey.

Abdulkadir Çoban (A)

Department of Biochemistry, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.

Bahadır Suleyman (B)

Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.

Renad Mammadov (R)

Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.

Halis Suleyman (H)

Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH